7.105
11.48%
-0.905
Vir Biotechnology Inc stock is traded at $7.105, with a volume of 1.55M.
It is down -11.48% in the last 24 hours and down -7.07% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$8.01
Open:
$8.01
24h Volume:
1.55M
Relative Volume:
1.70
Market Cap:
$1.06B
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.5824
EPS:
-4.49
Net Cash Flow:
$-473.07M
1W Performance:
-28.16%
1M Performance:
-7.07%
6M Performance:
-27.12%
1Y Performance:
-26.82%
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
VIR | 7.10 | 1.06B | 62.04M | -533.34M | -473.07M | -4.49 |
VRTX | 467.20 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.34 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 565.93 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.51 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.13 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Sep-14-22 | Initiated | SVB Leerink | Outperform |
Sep-09-22 | Initiated | Morgan Stanley | Underweight |
Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
Jun-04-21 | Resumed | Robert W. Baird | Neutral |
Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
Oct-05-20 | Initiated | BofA Securities | Buy |
Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
Aug-20-20 | Initiated | Needham | Buy |
Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-14-19 | Initiated | Robert W. Baird | Neutral |
Nov-05-19 | Initiated | Barclays | Overweight |
Nov-05-19 | Initiated | Cowen | Outperform |
Nov-05-19 | Initiated | Goldman | Buy |
Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat
(VIR) Proactive Strategies - Stock Traders Daily
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance
Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com
Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India
Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK
Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat
HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com India
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $26.00 by Analysts at Barclays - MarketBeat
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Misses Estimates By $0.51 EPS - MarketBeat
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Vir Biotechnology Q3 2024 Earnings Preview - MSN
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials By Investing.com - Investing.com South Africa
Stock Traders Buy High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials - Investing.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down on Disappointing Earnings - MarketBeat
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat
Vir Biotechnology Reports Q3 2024 Financial Results - TipRanks
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - BioSpace
Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c - StreetInsider.com
Trend Tracker for (VIR) - Stock Traders Daily
Vir Biotechnology (VIR) to Release Earnings on Thursday - MarketBeat
State Street Corp's Strategic Acquisition in Vir Biotechnology Inc - Yahoo Finance
State Street Corp's Strategic Acquisition in Vir Biotechnology I - GuruFocus.com
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 - BioSpace
Was there any good news for Vir Biotechnology Inc (VIR) stock in the last session? - US Post News
Possible Bearish Signals With Vir Biotechnology Insiders Disposing Stock - Simply Wall St
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024 - BioSpace
Vir Biotechnology to present hepatitis trial findings - Investing.com
Vir Biotechnology to present hepatitis trial findings By Investing.com - Investing.com South Africa
A History of Outperforming Analyst Forecasts and Beating the Odds: Vir Biotechnology Inc (VIR) - SETE News
Where are the Opportunities in (VIR) - Stock Traders Daily
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):